The Price of Global Health is a unique book that describes the pharmaceutical pricing process and its business, economic and social challenges. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death?

The pharmaceutical industry is under unprecedented pressure due to a combination of declining R&D productivity, payer/provider demands for better value and public pressures to show pricing restraint. Rapidly increasing cost of healthcare, shifts from fee-for-service to value-based reimbursement, public pressure on drug pricing and an increasingly vocal medical community have empowered public and private payers worldwide to be more demanding on evidence of value for the prescription drugs that are brought to market. Pharmaceutical companies have often failed to deliver evidence of patient value, as development decision-making is overly focused on speed to FDA approval rather than speed to commercial success by effectively addressing the many “Access Journey” obstacles that typify today’s much changed pharmaceutical environment.

This 3rd edition is significantly expanded with ten new chapters and revised and updated throughout to reflect today’s environment. The contents are reorganized to directly address critical pricing and patient access issues. Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences from healthcare industry professionals to policy makers, consumers, pharmaceutical company leaders and access and pricing professionals to gain a better understanding of this highly complex and emotionally charged field.

part Part A|60 pages

The challenges of drug pricing

chapter 1|28 pages

Why is drug pricing different?

ByEd Schoonveld

chapter 2|10 pages

The age of value and affordability

ByEd Schoonveld

chapter 3|10 pages

The Access Journey

ByEd Schoonveld

chapter 4|11 pages

Fair pricing

ByEd Schoonveld

part Part B|32 pages

Traveling the Access Journey

chapter 5|12 pages


ByEd Schoonveld

chapter 6|7 pages

Medical community

ByEd Schoonveld

chapter 7|5 pages

Provider organizations

ByEd Schoonveld

chapter 8|4 pages


ByEd Schoonveld

part Part C|54 pages

Pricing and payer management techniques

chapter 9|16 pages

Fundamentals of pricing

ByEd Schoonveld

chapter 10|8 pages

Reference-based pricing

ByEd Schoonveld

chapter 11|15 pages

Health economics and outcomes research

ByEd Schoonveld

chapter 12|13 pages

Attributes, benefits, value and price

ByEd Schoonveld

part Part D|112 pages

Structured access and pricing approaches

chapter 13|24 pages

Pricing and drug development

ByEd Schoonveld

chapter 14|20 pages

Payer segmentation

ByEd Schoonveld

chapter 15|11 pages

The PODiUM framework

ByEd Schoonveld

chapter 16|26 pages

BEST framework

ByEd Schoonveld

chapter 17|9 pages

Drug development options and decisions

ByEd Schoonveld

chapter 18|19 pages

Value story and messaging

ByEd Schoonveld

part Part E|87 pages

Developing an integrated global strategy

chapter 19|23 pages

Developing a global pricing strategy

ByEd Schoonveld

chapter 20|13 pages

Public policy

ByEd Schoonveld

chapter 21|12 pages

Oncology and orphan drugs

ByEd Schoonveld

chapter 22|6 pages

Gene and cell therapies

ByEd Schoonveld

chapter 23|5 pages


ByEd Schoonveld

chapter 24|24 pages

Payer and pricing research

ByEd Schoonveld

part Part F|45 pages

Access and pricing strategy implementation

chapter 25|12 pages

Organizing for access

ByEd Schoonveld

chapter 26|12 pages

Access and price negotiations

ByEd Schoonveld

chapter 27|12 pages

Value-based agreements

ByEd Schoonveld

chapter 28|8 pages

Creating win-win partnerships

ByEd Schoonveld

part Part G|157 pages

Key healthcare systems

chapter 29|31 pages

United States

ByEd Schoonveld, Michael Gonzalez

chapter 30|13 pages


ByEd Schoonveld, Jennifer Wong

chapter 31|12 pages


ByEd Schoonveld, Emmanuel Colliot

chapter 32|13 pages


ByEd Schoonveld, Stefan Kloss

chapter 33|12 pages


ByEd Schoonveld, Gianluigi Menale

chapter 34|7 pages


ByEd Schoonveld, Gianluigi Menale, Valeria Suppini

chapter 35|9 pages

United Kingdom

ByEd Schoonveld, Smita Sealey

chapter 36|15 pages


ByEd Schoonveld, Joe Stevens, Yomogi Torikai, Megan Sadiua

chapter 37|5 pages


ByEd Schoonveld, Smita Sealey, Nikhil Taxak

chapter 38|7 pages


ByEd Schoonveld, Gianluigi Menale, Valeria Suppini

chapter 39|5 pages


ByEd Schoonveld, Emmanuel Colliot, Aseem Afsah

chapter 40|9 pages


ByEd Schoonveld, Priygun Jain, Pooja Khandekar

chapter 41|8 pages

South Korea

ByEd Schoonveld, Priygun Jain, Pooja Khandekar